Liraglutide is a long-acting GLP-1 receptor agonist developed for the treatment of type 2 diabetes and chronic weight management. With proven clinical efficacy and a favorable safety profile, it is widely recognized in the pharmaceutical industry as a reliable therapeutic option for metabolic disorders.

Key Features:

• Glycemic Control: Effectively lowers blood glucose levels by enhancing insulin secretion and reducing glucagon production.

• Appetite Regulation: Delays gastric emptying and promotes satiety, contributing to sustainable weight loss.

• Once-Daily Dosing: Designed for convenient, once-daily subcutaneous injection.

• Clinically Proven: Backed by robust clinical studies and approved by regulatory agencies in multiple countries.

Applications:

• Treatment of Type 2 Diabetes Mellitus

• Weight Management in patients with obesity or overweight with related conditions

• Used in pharmaceutical formulations for injectable therapies